Late-stage clinical trials for novel RNA-based therapeutics have demonstrated strong efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH).
Efficacy Metrics
Patients receiving monthly subcutaneous injections achieved a 45% mean reduction in hepatic fat content over 48 weeks, compared to 12% in the placebo cohort. Key secondary endpoints, including fibrosis regression, met statistical significance without triggering major adverse events.
Commercialization Pipeline
Regulatory submissions to the FDA and EMA are scheduled for early next year. Healthcare equity analysts project peak annual sales exceeding $4.5 billion by 2029, given the limited availability of competing approved therapies.